| ID Source | ID |
|---|---|
| PubMed CID | 3081391 |
| CHEBI ID | 24108 |
| SCHEMBL ID | 5385410 |
| MeSH ID | M0103115 |
| Synonym |
|---|
| glycine, n-(1-deoxy-d-fructos-1-yl)- |
| fructose glycine |
| CHEBI:24108 |
| fructosyl-glycine |
| 1-[(carboxymethyl)amino]-1-deoxy-d-fructose |
| 4429-05-4 |
| fructosylglycine |
| FRUCTOSEGLYCINE , |
| n-(1-deoxy-d-fructos-1-yl)glycine |
| 2-[[(3s,4r,5r)-3,4,5,6-tetrahydroxy-2-oxohexyl]amino]acetic acid |
| SCHEMBL5385410 |
| DTXSID70196101 |
| n-(1-deoxy-d-fructos-1-yl)-glycine |
| Q27109831 |
| Role | Description |
|---|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| fructosamine | |
| glyco-amino acid | |
| glycine derivative | A proteinogenic amino acid derivative resulting from reaction of glycine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||